• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Syapse and Pierian Partner to Power Precision Oncology

by Strategic Partnerships 06/14/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Syapse, a real-world evidence company is teaming up with Pierian®, a provider of advanced clinical genomics technology on a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida.

– The collaboration combines Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer, Pierian’s leading-edge clinical genomics workflow, and precision medicine services that provide the most relevant insights in the industry.

Comprehensive Diagnostics for Oncology Patients in Central Florida

This partnership will enable AdventHealth clinicians to offer more comprehensive diagnostics for oncology patients in Central Florida, allowing more personalized treatment options due to improved capabilities to identify known and emerging biomarkers critical for cancer treatment and progression. It will also enable more efficient identification of clinical trials and treatment options for patients based on their molecular testing results and similar patients in the Syapse Learning Health Network (LHN). Syapse and Pierian will collaborate on optimizing AdventHealth’s internal genomic testing capabilities for all patients who may benefit to improve the actionable insights gathered from test orders and genomic results allowing a deeper understanding of the relationship between these insights and real patient outcomes.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biomarkers, cancer, Clinical Genomics, Clinical Trials, Genomic Testing, genomics, Oncology, Precision Medicine, Precision Oncology, Syapse

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Olive Secures $400M At A $4B Valuation to Support New Instant Claim Payment Solution

Olive Shutters Business After Sale to Waystar and Humata Health

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

FDA Grants Clearance for UltraSight's AI Cardiac Ultrasound

Israel Defense Forces to Utilize UltraSight’s PoCUS Devices in Combat

The Future of Biomarker-Based Therapy for Mental Disorder Care

The Future of Biomarker-Based Therapy for Mental Disorder Care

HLTH23: 6 Digital Health Executives Share Key Takeaways

6 Digital Health Executives Share Key Takeaways from HLTH23

HIMSS Appoints New Chief Financial Officer & General Counsel

HIMSS Appoints New Chief Financial Officer & General Counsel

GoodRx Now Offers Access to $35 Insulin to All Americans

GoodRx Now Offers Access to $35 Insulin to All Americans

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Health M&A: Financial Distress Driving Q3 Healthcare Deals

Health M&A: Financial Distress Driving Q3 Healthcare Deals

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |